Fibrodysplasia Ossificans Progressiva — Research Summary
Printed from RareWays (rareways.com.au) on 11 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Fear of progression profiles in parents of children with cancer and their impact on psychological distress: The mediating role of sense of coherence.
Ma Guiyuan et al. — Asia-Pacific journal of oncology nursing (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41953235/
- 2.
Trajectories and predictors of psycho-social adjustment in patients post hepatocellular carcinoma surgery: A longitudinal study.
Li Min et al. — Journal of psychosomatic research (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42070418/
- 3.
Disrupted left frontal operculum connectivity in adolescent depression: Mediating the impact of childhood emotional neglect.
Hu Yannan et al. — Journal of affective disorders (15 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41935748/
- 4.
Serpinh1 promotes fracture healing by enhancing osteogenesis via activation of the Wnt/β-catenin signaling pathway.
Tu Zhehui et al. — Biochemical and biophysical research communications (9 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42102673/
- 5.
Single-Cell dissection of fibrodysplasia ossificans progressiva identifies SPP1 as a mediator of macrophage-fibroadipogenic progenitors crosstalk.
Gamberale Riccardo et al. — Cellular and molecular life sciences : CMLS (2 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42393387/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Recruiting — Phase 2 — Incyte Corporation
https://clinicaltrials.gov/study/NCT05090891
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Fibrodysplasia Ossificans Progressiva
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition caused by ACVR1 mutations, causing muscles, tendons, and ligaments to progressively turn into bone. Any injury or surgery triggers new bone formation. Palovarotene, the first approved treatment, reduces the volume of new heterotopic bone.
Most Recent Research
OBJECTIVE: To identify latent profiles of Fear of Progression (FoP) in parents of children with cancer, explore their associated factors, and test the mediating role of Sense of Coherence (SOC) between FoP and psychological distress (PD). METHODS: A cross-sectional study was conducted with 273 parents of children with cancer in China. We used latent profile analysis (LPA) to identify FoP profiles, multinomial logistic regression to determine associated factors, and mediation analysis to test the role of SOC. RESULTS: Three distinct FoP profiles were identified: medication sensitive with low fear (38%), treatment sensitive with moderate fear (21%), and overall high fear (41%). These profiles were significantly differentiated by disease-related (e.g., treatment history), individual-related, and interpersonal-related (e.g., self-disclosure) factors. Across the sample, higher FoP was associated with greater PD. Importantly, mediation analyses revealed that SOC significantly mediated the relationship between FoP and PD for the moderate and high FoP profiles, but not for the low LoP profile. CONCLUSIONS: Parents of children with cancer exhibit heterogeneous FoP profiles. SOC acts as a crucial mediator between FoP and PD, particularly for parents with moderate and high FoP profiles. These findings underscore the importance of screening for specific FoP profiles and suggest that tailored interventions designed to enhance SOC could effectively reduce PD in high-risk parents.
Common Questions
What is Fibrodysplasia Ossificans Progressiva?
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition caused by ACVR1 mutations, causing muscles, tendons, and ligaments to progressively turn into bone. Any injury or surgery triggers new bone formation. Palovarotene, the first approved treatment, reduces the volume of new heterotopic bone.
How many clinical trials are available for Fibrodysplasia Ossificans Progressiva?
RareWays currently indexes 23 clinical trials for Fibrodysplasia Ossificans Progressiva, of which 5 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Fibrodysplasia Ossificans Progressiva come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Fibrodysplasia Ossificans Progressiva.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.